Overview
Research context and commercial specification.
A conjugated bile acid with a well-established function as a chemical chaperone, assisting protein folding in the endoplasmic reticulum and buffering proteotoxic stress. Tauroursodeoxycholic acid is studied across hepatic, metabolic and neurodegenerative research, where it is used as a probe of cellular stress response rather than as a target-specific agent. It anchors the portfolio's interest in how cells respond when repair becomes the priority.
Research direction
At a glance
| CAS number | 14605-22-2 |
| INCI name | Tauroursodeoxycholic Acid |
| Molecular formula | C26H45NO6S |
| Molecular weight | 499.70 g/mol |
| Purity | ≥98.0% |
| Appearance | White powder |
| Grade | Pharma grade / Research grade |
| Solubility | Freely soluble in water and ethanol |
| Storage | Cool, dry, protected from light — 25 °C |
| Shelf life | 36 months unopened |
| Packaging | 25 kg / drum |
| Origin | Bile-acid derived, multi-stage purification |
| Analytical methods | HPLC (purity, assay) · LC-MS (identity) · Residual solvents (GC) |
| Certification | ISO 9001 · GMP |
Published references
This library is synchronized from PubMed and shows bibliographic metadata only (title, authors, journal, year, link). No abstract or full text is reproduced. Papers flagged as context-dependent are included for scientific completeness and require careful interpretation.
-
Front Immunol2026Context-dependent — read with careCase Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizumab and ursodeoxycholic acid.This paper reports associations or intervention outcomes in a specific model or population. It is presented for research context only and is not a claim about any finished product.Open in PubMed →
-
Front Pharmacol2026Context-dependent — read with careHepatoprotective mechanism of tauroursodeoxycholic acid and its therapeutic potential in liver diseases.This paper reports associations or intervention outcomes in a specific model or population. It is presented for research context only and is not a claim about any finished product.Open in PubMed →
-
Hepatology2026Context-dependent — read with careTreatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.This paper reports associations or intervention outcomes in a specific model or population. It is presented for research context only and is not a claim about any finished product.Open in PubMed →
-
Int J Mol Sci2026Reassessment of Neuroprotective Efficacy of TUDCA in Ischemic Stroke: A Multi-Model In Vivo and In Vitro Study.Open in PubMed →
Technical questions
What is tauroursodeoxycholic acid?
How is it supplied?
Which application contexts is it positioned in?
Ask about this active
Request the complete specification dossier, a sample, or formulation guidance for Creatrich Biotech actives.